Schedules of Controlled Substances: Placement of 3-MeO-PCP in Schedule I
The DEA has placed 3-MeO-PCP in Schedule I due to its high abuse potential and lack of accepted medical use. This regulatory action addresses emerging synthetic drugs like 3-MeO-PCP that pose public health risks. Clinicians should be aware of 3-MeO-PCP…
France Sets July Deadline for Medical Cannabis Regulations as Withheld Study Shows …
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchSafetyIndustryPainAnxietyNeurology Why This Matters I need the complete article summary to provide an…
Schedules of Controlled Substances: DEA Synthetic Cannabinoids Schedule I Placement 2026
The DEA synthetic cannabinoids Schedule I placement 2026 update includes MDMB-4en-PINACA due to its high abuse potential and health risks. This scheduling reflects efforts to regulate emerging synthetic cannabinoids posing public health challenges.…
7 unexpected takeaways from the newest research on cannabis and brain effects
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologyMental HealthTHCSafetyAnxietySleep Why This Matters Clinicians need to understand emerging neuroscience…
Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products to Schedule III
The DEA rescheduling cannabis products from Schedule I to Schedule III marks a pivotal regulatory change. This shift applies to FDA-approved cannabis-derived medications, easing prescribing and research barriers. Clinicians should note this change…
Relationships between cannabis use and mental disorders: assessing the coherence of …
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. Mental HealthResearchAnxietyTHCSafetyPediatricsNeurology Why This Matters I can see the title references cannabis use and…
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
The DEA synthetic cannabinoids schedule I placement 2026 marks a critical regulatory update addressing new designer drugs. This action highlights the growing concern over synthetic cannabinoids' abuse potential and clinical risks. Clinicians should be…
PleoPharma, Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of PP-01 …
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthSafetyDosingNeurologyAnxietyIndustry Why This Matters This pivotal Phase 3 trial represents the…
Schedules of Controlled Substances: DEA Update on Synthetic Cannabinoids
The DEA synthetic cannabinoids schedule I placement update designates cumyl-pegaclone as a high-risk substance with no accepted medical use. This update highlights ongoing challenges in regulating novel synthetic cannabinoids. Clinicians should be aware…
Fewer Employees Skip Work Days Where Medical Marijuana Is Legal, Especially For …
✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchMental HealthPainSafetyIndustryAnxiety Why This Matters Clinicians should understand that medical…